Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The compan… Read more
Skye Bioscience, Inc. Common Stock (SKYE) - Total Assets
Latest total assets as of September 2025: $41.32 Million USD
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) holds total assets worth $41.32 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Skye Bioscience, Inc. Common Stock - Total Assets Trend (2012–2024)
This chart illustrates how Skye Bioscience, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Skye Bioscience, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Skye Bioscience, Inc. Common Stock's total assets of $41.32 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.0% |
| Accounts Receivable | $5.07K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Skye Bioscience, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Skye Bioscience, Inc. Common Stock's current assets represent 97.3% of total assets in 2024, an increase from 89.4% in 2012.
- Cash Position: Cash and equivalents constituted 94.0% of total assets in 2024, up from 61.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Skye Bioscience, Inc. Common Stock Competitors by Total Assets
Key competitors of Skye Bioscience, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Skye Bioscience, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Skye Bioscience, Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Skye Bioscience, Inc. Common Stock is currently not profitable relative to its asset base.
Skye Bioscience, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.77 | 14.19 | 3.38 |
| Quick Ratio | 4.77 | 14.19 | 3.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $31.56 Million | $ 74.18 Million | $ 1.88 Million |
Skye Bioscience, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Skye Bioscience, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 509.4% |
| Total Assets | $72.76 Million |
| Market Capitalization | $13.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Skye Bioscience, Inc. Common Stock's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Skye Bioscience, Inc. Common Stock's assets grew by 509.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Skye Bioscience, Inc. Common Stock (2012–2024)
The table below shows the annual total assets of Skye Bioscience, Inc. Common Stock from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $72.76 Million | +509.39% |
| 2023-12-31 | $11.94 Million | +31.05% |
| 2022-12-31 | $9.11 Million | -7.55% |
| 2021-12-31 | $9.86 Million | +268.87% |
| 2020-12-31 | $2.67 Million | +33.80% |
| 2019-12-31 | $2.00 Million | +2.02% |
| 2018-12-31 | $1.96 Million | +251.23% |
| 2017-12-31 | $557.22K | +72.32% |
| 2016-12-31 | $323.36K | -90.79% |
| 2015-12-31 | $3.51 Million | +907.92% |
| 2014-12-31 | $348.35K | +139.09% |
| 2013-12-31 | $145.69K | +239.74% |
| 2012-12-31 | $42.88K | -- |